Compare two peptides side by side
Every profile on the site, two at a time: FDA status first, then the evidence behind it, then what each one is. Comparing results across different trials is only a rough guide; each profile explains the caveats.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Section | GLP-1s | GLP-1s |
| FDA status | FDA approved Mounjaro approved May 2022 for type 2 diabetes, with children 10 and older added to the label in December 2025, and on August 28, 2026 to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Zepbound, which does not have that indication, was approved November 2023 for chronic weight management and December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. | FDA approved Ozempic approved Dec 2017 and Rybelsus Sep 2019 for type 2 diabetes; Wegovy approved Jun 2021 for weight management, with heart-risk reduction (Mar 2024) and MASH (Aug 2025) added; Wegovy pill Dec 22 2025; Wegovy HD 7.2 mg Mar 19 2026. |
| Evidence level | FDA label Dosing comes from the FDA-approved prescribing information. | FDA label Dosing comes from the FDA-approved prescribing information. |
| What it is | A once-weekly injectable GIP and GLP-1 receptor agonist made by Eli Lilly, sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, obstructive sleep apnea). | A GLP-1 receptor agonist made by Novo Nordisk, sold as Wegovy injection and tablets (weight management, heart-risk reduction, MASH) and as Ozempic and Rybelsus (type 2 diabetes). |
| The short answer | Tirzepatide is a once-weekly injection from Eli Lilly that activates two gut-hormone receptors, GIP and GLP-1, sold as Zepbound for weight management and sleep apnea and as Mounjaro for type 2 diabetes. In the SURMOUNT-1 trial, people on 15 mg lost an average of 20.9% of body weight at 72 weeks, versus 3.1% on placebo. | Semaglutide is a GLP-1 drug sold as Wegovy for weight loss and as Ozempic for type 2 diabetes. In the STEP 1 trial, adults on Wegovy 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% on placebo. Without insurance, Wegovy costs $149 to $399 a month through Novo Nordisk. |
| Go deeper |
Statuses come from each profile and the FDA status tracker. This tool compares what the pages say; it does not rank or recommend.